Jose R. Rivas Rios, M.D.

Jose R. Rivas Rios M.D.

Assistant Professor

Department: Department of Medicine
Business Email: Jose.RivasRios@jax.ufl.edu
Appointments and Locations

Board Certifications

  • Internal Medicine
  • Cardiovascular Disease

Clinical Profile

Specialties
  • Cardiovascular Disease
Interests
  • Clinical Special Interests: Preventive Cardiology, Cardio-metabolic, Cardiology Imaging
  • Research Special Interests: Lipids, Antithrombotic Therapy
Languages
  • Speaks English and Spanish

Publications

2022
Aerococcus urinae Infective Endocarditis.
Cureus.14(4):e23947-[DOI] 10.7759/cureus.23947.[PMID] 35547451.
1 citations·PubMed·Publisher's Site
2022
New-onset heart failure masking a massive retroperitoneal liposarcoma.
Journal of geriatric cardiology : JGC.19(4):319-321[DOI] 10.11909/j.issn.1671-5411.2022.04.003.[PMID] 35572214.
PubMed·Publisher's Site
2021
Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study.
BMJ open diabetes research & care.9(1):-[DOI] 10.1136/bmjdrc-2020-001939.[PMID] 33637605.
12 citations·PubMed·Publisher's Site
2020
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.
Thrombosis and haemostasis.120(1):83-93[DOI] 10.1055/s-0039-1695772.[PMID] 31470444.
19 citations·PubMed·Publisher's Site
2020
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study.
Journal of the American Heart Association.9(8):e015865-[DOI] 10.1161/JAHA.120.015865.[PMID] 32306797.
19 citations·PubMed·Publisher's Site
2020
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing.
JACC. Basic to translational science.5(5):419-428[DOI] 10.1016/j.jacbts.2020.02.009.[PMID] 32478205.
19 citations·PubMed·Publisher's Site
2019
Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine.
JACC. Cardiovascular interventions.12(16):1538-1549[DOI] 10.1016/j.jcin.2019.05.028.[PMID] 31377269.
26 citations·PubMed·Publisher's Site
2019
Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study.
JACC. Basic to translational science.4(7):763-775[DOI] 10.1016/j.jacbts.2019.07.011.[PMID] 31998847.
14 citations·PubMed·Publisher's Site
2018
Diabetes and antiplatelet therapy: from bench to bedside.
Cardiovascular diagnosis and therapy.8(5):594-609[DOI] 10.21037/cdt.2018.05.09.[PMID] 30498684.
40 citations·PubMed·Publisher's Site
2018
Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study.
Circulation.137(23):2450-2462[DOI] 10.1161/CIRCULATIONAHA.118.033983.[PMID] 29526833.
43 citations·PubMed·Publisher's Site
2018
Role of genetic testing in patients undergoing percutaneous coronary intervention.
Expert review of clinical pharmacology.11(2):151-164[DOI] 10.1080/17512433.2017.1353909.[PMID] 28689434.
53 citations·PubMed·Publisher's Site

Office Information

Academic Office
Jose.RivasRios@jax.ufl.edu

Education

Medical Degree
Universidad del Zulia,, Maracaibo, Venezuela
Internal Medicine Residency
2020 · University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA
Cardiovascular Disease Fellowship
2023 · University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA